Zoely
ApprovedSmall molecule
Zoely is one of 69 small molecule programs targeting Contraception. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
175 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Metfomin
UUniversity of Texas Southwestern Medical Center
Phase 3
Zoely
MMahidol University
Approved
Sequential Lenvatinib
SSun Yat-sen University
Phase 3
Clomid
FerringPreclinical
Oral Contraceptive Pill
WWayne State University
Phase 3
Precose
BayerPreclinical
Proglycem
TevaPreclinical
Clomid
EMD SeronoPreclinical
Cetrotide
EMD SeronoPreclinical
Casodex
IIstituto Clinico Humanitas
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Contraception1 trial
Polycystic Ovary Syndrome1 trial
Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
Unknown status·—·Phase 1·NCT01603745·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zoely. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMahidol University